NEW YORK, January 30, 2017 /PRNewswire/ --
http://www.Financialbuzz.com - One of the more interesting sectorshas been biotechnology. Advances made in various field and technologies have been pushing the sector to vigorously invest in new platforms and clinical trials. For example, advances in DNA sequencing technologies are decreasing prices of the procedure
The research indicates that North America dominates, with revenue share in 2015 with over USD 137.4 billion owing to growing R&D initiatives by key industry players and rising awareness among public and private research institute. Europe biotechnology market share, along with APAC is projected to show growth during the coming years due to growing public health and introduction of healthcare benefits by government agencies in different countries.
Mount Tam Biotechnologies, Inc. (OTC: MNTM) is a developer and marketer of novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. The company's most advanced compound is being developed to treat systemic lupus erythematosus (SLE). Previously Mount Tam has partnered with the Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets involved are highly target specific polyketides - a class of compounds with a successful track record with the FDA drug approval process. Currently Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has completed non-GLP pre-clinical development.
On January 9th, Mount Tam announced that together with Cambridge, UK-based Isomerase Therapeutics Ltd, "have agreed to expand their research collaboration for the discovery and development of novel rapalogs in 2017. As part of this research collaboration, Mount Tam will work to characterize and advance discovery programs for a range of novel and proprietary rapalogs that have been developed through Isomerase's proprietary approach to improving microbial natural products via their unique biosynthetic medicinal chemistry platform."
The goal of the partnership is to discover and develop differentiated mTOR modulators that can improve upon currently marketed rapalogs. Richard Marshak, Mount Tam's CEO, said "We are excited by the opportunity to work with these novel rapalogs given the great potential for mTOR modulators to address a wide range of serious unmet medical needs across a range of therapeutic areas where satisfactory treatments are lacking. It is also rewarding to advance our collaboration with the team at Isomerase, one of the world's leaders in advancing microbial natural products".
Anthera Pharmaceuticals (NASDAQ: ANTH) is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company has two product candidates in development. Sollpura is Anthera's novel biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. Blisibimod is Anthera's BAFF inhibitor for the potential treatment of IgA nephropathy.
Biopharmaceutical Company, Protalix Biotherapeutics Inc. (NYSE: PLX) is focused on the development, production and commercialization of recombinant therapeutic proteins produced by their proprietary ProCellEx« plant cell-based protein expression system. Protalix's pipeline consists of proprietary, potentially clinically superior versions of recombinant therapeutic proteins that target established pharmaceutical markets. Its advanced clinical programs addresses Fabry disease, cystic fibrosis, and immune and inflammatory diseases. Further, Protalix conducts initial research to evaluate additional programs for developing proprietary proteins with improved clinical profiles exploiting the unique nature of plant cell expression.
Novavax Inc. (NASDAQ: NVAX) commenced initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate in older adults. The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine, with and without aluminum phosphate or Novavax` proprietary Matrix-M(TM) adjuvant, in older adults. The trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 300 older adults in the Southern Hemisphere. Participants are being enrolled and vaccinated outside of the RSV season to best assess immunogenicity. Top-line results are expected in the third quarter of 2017. "We believe that a more immunogenic vaccine in the older adult population should translate into a more efficacious vaccine," said Stanley C. Erck, President and CEO. "We expect the results from this trial to inform the next steps in our older adults program, and would ensure we maintain our leadership position in this very attractive market opportunity."
Tenax Therapeutics Inc. (NASDAQ: TENX) is a specialty pharmaceutical company focused on identifying, developing and commercializing products for critical care market. The Company owns North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com á
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: Media Contact: email@example.com , +1-877-601-1879
Subscribe to our Free Newsletters!
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All